<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044537</url>
  </required_header>
  <id_info>
    <org_study_id>B1621001</org_study_id>
    <nct_id>NCT01044537</nct_id>
  </id_info>
  <brief_title>A Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Doses Of PF-04937319 In Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1 Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Single Escalating Oral Doses Of Pf-04937319 In Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of PF-04937319 following single escalating oral doses in adult subjects with
      Type 2 Diabetes Mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this phase 1 study is to characterize the safety, tolerability,
      pharmacokinetics, and pharmacodynamics of PF04937319 following single escalating oral doses
      in adult subjects with T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to 10 days after last dose of study medication (up to 11 days)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study medication and up to 10 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
    <description>Area under the plasma concentration-time curve from zero to the last measured concentration (AUClast).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
    <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
    <description>Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
    <description>AUCinf is the area under the plasma concentration versus time curve from time zero to extrapolated infinite time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ratio of C-peptide Area Under Curve (C-peptide AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hours pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hours post-dose on Day 1</time_frame>
    <description>Ratio of area under the plasma C-peptide concentration-time curve from time 2 to 6 hrs (in terms of nanogram*deciliter*hour [ng*dL*hour]) to area under the plasma glucose concentration-time curve from time 2 to 6 hrs (in terms of milligram*milliliter*hour [mg*mL*hour]) was calculated. Linear trapezoidal method was used to compute AUC. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Post-Prandial Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
    <description>Percent change from baseline in post-prandial area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Post-Prandial Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
    <description>Percent change from baseline in post-prandial area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Post-Prandial C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
    <description>Percent change from baseline in post-prandial area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ratio of Insulin Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT) on Day 1</measure>
    <time_frame>-46, -45.5 hrs pre-dose on Day -1; 2, 2.5 hrs post-dose on Day 1</time_frame>
    <description>Ratio of insulin delta C30 (in terms of milliunits*deciliter [mU*dL]) to glucose delta C30 (in terms of milligram*liter [mg*liter]) was calculated. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ratio of C-peptide Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT)</measure>
    <time_frame>-46, -45.5 hrs pre-dose on Day -1; 2, 2.5 hrs post-dose on Day 1</time_frame>
    <description>Ratio of C-peptide Delta C30 (in terms of nanogram*deciliter [ng*dL]) to glucose delta C30 (in terms of milligram*milliliter [mg*mL]) was calculated. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1</measure>
    <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
    <description>Ratio of area under the plasma insulin concentration-time curve from time 2 to 6 hrs (in terms of milliunit*deciliter*hour [mU*dL*hour]) to area under the plasma glucose concentration-time curve from time 2 to 6 hrs (in terms of milligram*liter*hour [mg*liter*hour]) was calculated. Linear trapezoidal method was used to compute AUC. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-04937319</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match PF-04937319 will be provided.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04937319</intervention_name>
    <description>The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.</description>
    <arm_group_label>PF-04937319</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type 2 diabetes mellitus who are taking stable doses of metformin only.
             Subjects treated with a sulfonylurea (SU) or a dipeptidyl peptidase-IV inhibitor
             (DPP-IVi) in combination with metformin may be eligible if washed off the SU or
             DPP-IVi to metformin only for a minimum of 4 weeks before dosing.

          -  Male and/or female subjects (females will be women of non childbearing potential)
             between the ages of 18 and 65 years, inclusive, with a body mass index (BMI) of 18.5
             to 45.0 kg/m2 and C-peptide &gt;0.8 ng/mL.

          -  Screening and Day -2 troponin I concentration &lt;/=0.05 ng/mL as measured by the Bayer
             Centaur Ultra assay.

          -  HbA1c &gt;/=7% and &lt;/=11%. If the patient requires to be washed off an SU or DPP-IVi, the
             HbA1c limits will be &gt;/=7% and &lt;/=9.5%.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Evidence or history of diabetic complications with significant end organ damage, eg,
             proliferative retinopathy and/or macular edema, creatinine clearance &lt;/=60 mL/min
             based on the Cockcroft-Gault equation, diabetic neuropathy complicated by neuropathic
             ulcers.

          -  History of stroke, transient ischemic attack, or myocardial infarction within the past
             6 months. Additionally, history of coronary artery bypass graft or stent implantation,
             clinically significant peripheral vascular disease, or congestive heart failure (NYHA
             Classes II-IV). Furthermore, a current history of angina/unstable angina. Also, 12
             lead electrocardiogram (ECG) demonstrating QTc &gt;450 msec at screening, ECG findings
             suggestive of asymptomatic myocardial ischemia, or supine blood pressure &gt;/=160 mm Hg
             (systolic) or &lt;/=100 mm Hg (diastolic).

          -  One or more self reported episodes of hypoglycemia within the last 3 months, or two or
             more self reported episodes of hypoglycemia within the last 6 months.

          -  Screening or Day -2 fasting (&gt;/=8 hours) blood glucose, &lt;/=70 or &gt;/=270 mg/dL,
             confirmed by a single repeat if deemed necessary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dedicated Phase 1</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials, LLC</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1621001&amp;StudyName=A%20Trial%20To%20Assess%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%2C%20And%20Pharmacodynamics%20Of%20Single%20Doses%20Of%20PF-04937319%20In%20Subjects%20With%20T</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>January 20, 2017</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase 1</keyword>
  <keyword>safety and tolerability</keyword>
  <keyword>PK</keyword>
  <keyword>PD</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>T2DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PF-04937319 10 mg</title>
          <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>PF-04937319 30 mg</title>
          <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>PF-04937319 100 mg</title>
          <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>PF-04937319 300 mg</title>
          <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>PF-04937319 480 mg</title>
          <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>PF-04937319 640 mg</title>
          <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Placebo</title>
          <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>PF-04937319 10 mg</title>
          <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>PF-04937319 30 mg</title>
          <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>PF-04937319 100 mg</title>
          <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>PF-04937319 300 mg</title>
          <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>PF-04937319 480 mg</title>
          <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>PF-04937319 640 mg</title>
          <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Placebo</title>
          <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="5"/>
            <count group_id="B7" value="16"/>
            <count group_id="B8" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="9.0"/>
                    <measurement group_id="B2" value="52.2" spread="8.8"/>
                    <measurement group_id="B3" value="52.0" spread="6.8"/>
                    <measurement group_id="B4" value="58.8" spread="4.6"/>
                    <measurement group_id="B5" value="55.0" spread="8.1"/>
                    <measurement group_id="B6" value="49.0" spread="10.0"/>
                    <measurement group_id="B7" value="53.7" spread="7.8"/>
                    <measurement group_id="B8" value="53.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study medication and up to 10 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
        <time_frame>Day 1 up to 10 days after last dose of study medication (up to 11 days)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study medication and up to 10 days after last dose that were absent before treatment or that worsened relative to pretreatment state.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ratio of C-peptide Area Under Curve (C-peptide AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
        <description>Ratio of area under the plasma C-peptide concentration-time curve from time 2 to 6 hrs (in terms of nanogram*deciliter*hour [ng*dL*hour]) to area under the plasma glucose concentration-time curve from time 2 to 6 hrs (in terms of milligram*milliliter*hour [mg*mL*hour]) was calculated. Linear trapezoidal method was used to compute AUC. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hours pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hours post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. 'N' (number of participants analyzed) signifies participants evaluable for this measure and ‘n’ signifies participants evaluable at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ratio of C-peptide Area Under Curve (C-peptide AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
          <description>Ratio of area under the plasma C-peptide concentration-time curve from time 2 to 6 hrs (in terms of nanogram*deciliter*hour [ng*dL*hour]) to area under the plasma glucose concentration-time curve from time 2 to 6 hrs (in terms of milligram*milliliter*hour [mg*mL*hour]) was calculated. Linear trapezoidal method was used to compute AUC. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. 'N' (number of participants analyzed) signifies participants evaluable for this measure and ‘n’ signifies participants evaluable at specified time point for each arm group, respectively.</population>
          <units>(ng*dL*hour)/(mg*mL*hour)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 5,6,6,6,5,5,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.012"/>
                    <measurement group_id="O2" value="0.03" spread="0.014"/>
                    <measurement group_id="O3" value="0.03" spread="0.020"/>
                    <measurement group_id="O4" value="0.03" spread="0.009"/>
                    <measurement group_id="O5" value="0.03" spread="0.009"/>
                    <measurement group_id="O6" value="0.03" spread="0.009"/>
                    <measurement group_id="O7" value="0.03" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1 (n= 5,5,6,6,5,5,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.002"/>
                    <measurement group_id="O2" value="0.00" spread="0.004"/>
                    <measurement group_id="O3" value="0.00" spread="0.013"/>
                    <measurement group_id="O4" value="0.01" spread="0.003"/>
                    <measurement group_id="O5" value="0.01" spread="0.005"/>
                    <measurement group_id="O6" value="0.01" spread="0.008"/>
                    <measurement group_id="O7" value="0.00" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
        <description>Area under the plasma concentration-time curve from zero to the last measured concentration (AUClast).</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>Pharmacokinetic (PK) parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</title>
          <description>Area under the plasma concentration-time curve from zero to the last measured concentration (AUClast).</description>
          <population>Pharmacokinetic (PK) parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475.2" spread="13"/>
                    <measurement group_id="O2" value="1362" spread="34"/>
                    <measurement group_id="O3" value="4418" spread="21"/>
                    <measurement group_id="O4" value="10640" spread="33"/>
                    <measurement group_id="O5" value="10830" spread="29"/>
                    <measurement group_id="O6" value="19970" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.29" spread="25"/>
                    <measurement group_id="O2" value="124.9" spread="17"/>
                    <measurement group_id="O3" value="339.8" spread="34"/>
                    <measurement group_id="O4" value="756.6" spread="59"/>
                    <measurement group_id="O5" value="769.9" spread="50"/>
                    <measurement group_id="O6" value="1050" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="1.95" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.50" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.95" upper_limit="8.00"/>
                    <measurement group_id="O4" value="3.50" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="1.92" upper_limit="6.00"/>
                    <measurement group_id="O6" value="7.98" lower_limit="3.00" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F)</title>
        <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F)</title>
          <description>Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
          <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>milliliter per minute (mL/min)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344.8" spread="13"/>
                    <measurement group_id="O2" value="360.9" spread="37"/>
                    <measurement group_id="O3" value="364.4" spread="26"/>
                    <measurement group_id="O4" value="464.2" spread="40"/>
                    <measurement group_id="O5" value="690.3" spread="28"/>
                    <measurement group_id="O6" value="481.8" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vz/F)</title>
        <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F)</title>
          <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.</description>
          <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.0" spread="12"/>
                    <measurement group_id="O2" value="204.6" spread="42"/>
                    <measurement group_id="O3" value="254.4" spread="25"/>
                    <measurement group_id="O4" value="284.1" spread="76"/>
                    <measurement group_id="O5" value="379.2" spread="25"/>
                    <measurement group_id="O6" value="399.3" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Decay Half-Life (t1/2)</title>
        <description>Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Decay Half-Life (t1/2)</title>
          <description>Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half.</description>
          <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.203" spread="0.74888"/>
                    <measurement group_id="O2" value="6.592" spread="0.79893"/>
                    <measurement group_id="O3" value="8.632" spread="3.3756"/>
                    <measurement group_id="O4" value="7.366" spread="2.4225"/>
                    <measurement group_id="O5" value="6.410" spread="1.0422"/>
                    <measurement group_id="O6" value="12.79" spread="6.3392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Post-Prandial Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
        <description>Percent change from baseline in post-prandial area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Post-Prandial Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
          <description>Percent change from baseline in post-prandial area under the plasma glucose concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" spread="8.428"/>
                    <measurement group_id="O2" value="-15.22" spread="8.887"/>
                    <measurement group_id="O3" value="4.96" spread="31.567"/>
                    <measurement group_id="O4" value="-11.72" spread="8.350"/>
                    <measurement group_id="O5" value="-10.81" spread="10.017"/>
                    <measurement group_id="O6" value="-23.21" spread="10.207"/>
                    <measurement group_id="O7" value="-0.45" spread="13.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Post-Prandial Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
        <description>Percent change from baseline in post-prandial area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Post-Prandial Insulin Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
          <description>Percent change from baseline in post-prandial area under the plasma insulin concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here 'N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.98" spread="21.327"/>
                    <measurement group_id="O2" value="10.72" spread="13.424"/>
                    <measurement group_id="O3" value="0.22" spread="26.086"/>
                    <measurement group_id="O4" value="2.03" spread="15.622"/>
                    <measurement group_id="O5" value="35.61" spread="28.235"/>
                    <measurement group_id="O6" value="9.30" spread="38.556"/>
                    <measurement group_id="O7" value="6.35" spread="25.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Post-Prandial C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
        <description>Percent change from baseline in post-prandial area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here ‘N’ (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Post-Prandial C-peptide Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
          <description>Percent change from baseline in post-prandial area under the plasma C-peptide concentration-time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC. Baseline value was the AUC (2-6) calculated on Day -1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here ‘N’ (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.10" spread="3.749"/>
                    <measurement group_id="O2" value="-0.63" spread="14.664"/>
                    <measurement group_id="O3" value="1.79" spread="17.426"/>
                    <measurement group_id="O4" value="8.23" spread="8.101"/>
                    <measurement group_id="O5" value="21.13" spread="8.037"/>
                    <measurement group_id="O6" value="12.51" spread="19.188"/>
                    <measurement group_id="O7" value="6.09" spread="18.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ratio of Insulin Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
        <description>Ratio of insulin delta C30 (in terms of milliunits*deciliter [mU*dL]) to glucose delta C30 (in terms of milligram*liter [mg*liter]) was calculated. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
        <time_frame>-46, -45.5 hrs pre-dose on Day -1; 2, 2.5 hrs post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ratio of Insulin Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
          <description>Ratio of insulin delta C30 (in terms of milliunits*deciliter [mU*dL]) to glucose delta C30 (in terms of milligram*liter [mg*liter]) was calculated. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>(mU*dL)/(mg*Liter)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.627"/>
                    <measurement group_id="O2" value="4.59" spread="6.935"/>
                    <measurement group_id="O3" value="1.92" spread="2.759"/>
                    <measurement group_id="O4" value="0.77" spread="0.289"/>
                    <measurement group_id="O5" value="0.73" spread="0.265"/>
                    <measurement group_id="O6" value="0.85" spread="0.631"/>
                    <measurement group_id="O7" value="1.15" spread="0.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.427"/>
                    <measurement group_id="O2" value="-3.20" spread="7.093"/>
                    <measurement group_id="O3" value="-0.81" spread="1.891"/>
                    <measurement group_id="O4" value="0.25" spread="0.090"/>
                    <measurement group_id="O5" value="1.89" spread="3.894"/>
                    <measurement group_id="O6" value="0.74" spread="0.675"/>
                    <measurement group_id="O7" value="-0.05" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ratio of C-peptide Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT)</title>
        <description>Ratio of C-peptide Delta C30 (in terms of nanogram*deciliter [ng*dL]) to glucose delta C30 (in terms of milligram*milliliter [mg*mL]) was calculated. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
        <time_frame>-46, -45.5 hrs pre-dose on Day -1; 2, 2.5 hrs post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ratio of C-peptide Delta C30 to Glucose Delta C30 After a Mixed Meal Tolerance Test (MMTT)</title>
          <description>Ratio of C-peptide Delta C30 (in terms of nanogram*deciliter [ng*dL]) to glucose delta C30 (in terms of milligram*milliliter [mg*mL]) was calculated. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>(ng*dL)/(mg*mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.034"/>
                    <measurement group_id="O2" value="0.16" spread="0.293"/>
                    <measurement group_id="O3" value="0.05" spread="0.064"/>
                    <measurement group_id="O4" value="0.03" spread="0.011"/>
                    <measurement group_id="O5" value="0.02" spread="0.008"/>
                    <measurement group_id="O6" value="0.05" spread="0.038"/>
                    <measurement group_id="O7" value="0.04" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.018"/>
                    <measurement group_id="O2" value="-0.12" spread="0.283"/>
                    <measurement group_id="O3" value="-0.02" spread="0.050"/>
                    <measurement group_id="O4" value="0.01" spread="0.006"/>
                    <measurement group_id="O5" value="0.13" spread="0.240"/>
                    <measurement group_id="O6" value="0.02" spread="0.029"/>
                    <measurement group_id="O7" value="0.00" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
        <description>Ratio of area under the plasma insulin concentration-time curve from time 2 to 6 hrs (in terms of milliunit*deciliter*hour [mU*dL*hour]) to area under the plasma glucose concentration-time curve from time 2 to 6 hrs (in terms of milligram*liter*hour [mg*liter*hour]) was calculated. Linear trapezoidal method was used to compute AUC. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
        <time_frame>-46, -45.75, -45.5, -45, -44.5, -44, -43, -42 hrs pre-dose on Day -1; 2, 2.25, 2.5, 3, 3.5, 4, 5, 6 hrs post-dose on Day 1</time_frame>
        <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. ‘N' (number of participants analyzed) signifies participants evaluable for this measure and ‘n’ signifies participants evaluable at specified time point for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ratio of Insulin Area Under Curve (Insulin AUC) to Glucose Area Under Curve (Glucose AUC) After a Mixed Meal Tolerance Test (MMTT) on Day 1</title>
          <description>Ratio of area under the plasma insulin concentration-time curve from time 2 to 6 hrs (in terms of milliunit*deciliter*hour [mU*dL*hour]) to area under the plasma glucose concentration-time curve from time 2 to 6 hrs (in terms of milligram*liter*hour [mg*liter*hour]) was calculated. Linear trapezoidal method was used to compute AUC. The change in ratio from baseline (Day -1) was calculated at Day 1.</description>
          <population>PD analysis population included all enrolled participants who received at least 1 dose of study medication and had at least 1 of the PD parameters of interest. ‘N' (number of participants analyzed) signifies participants evaluable for this measure and ‘n’ signifies participants evaluable at specified time point for each arm group, respectively.</population>
          <units>(mU*dL*hour)/(mg*liter*hour)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 5,5,6,6,5,5,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.118"/>
                    <measurement group_id="O2" value="0.32" spread="0.257"/>
                    <measurement group_id="O3" value="0.48" spread="0.452"/>
                    <measurement group_id="O4" value="0.36" spread="0.142"/>
                    <measurement group_id="O5" value="0.29" spread="0.085"/>
                    <measurement group_id="O6" value="0.38" spread="0.310"/>
                    <measurement group_id="O7" value="0.34" spread="0.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 1 (n= 5,4,6,5,5,5,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.036"/>
                    <measurement group_id="O2" value="0.10" spread="0.104"/>
                    <measurement group_id="O3" value="-0.12" spread="0.235"/>
                    <measurement group_id="O4" value="0.04" spread="0.062"/>
                    <measurement group_id="O5" value="0.16" spread="0.104"/>
                    <measurement group_id="O6" value="0.10" spread="0.169"/>
                    <measurement group_id="O7" value="0.01" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</title>
        <description>AUCinf is the area under the plasma concentration versus time curve from time zero to extrapolated infinite time.</description>
        <time_frame>0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48 hours post-dose</time_frame>
        <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-04937319 10 mg</title>
            <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PF-04937319 30 mg</title>
            <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PF-04937319 100 mg</title>
            <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>PF-04937319 300 mg</title>
            <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>PF-04937319 480 mg</title>
            <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>PF-04937319 640 mg</title>
            <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)</title>
          <description>AUCinf is the area under the plasma concentration versus time curve from time zero to extrapolated infinite time.</description>
          <population>PK parameter analysis population included all enrolled participants who received study medication and had at least 1 of the PK parameters of interest. Here ‘N' (number of participants analyzed) signifies participants evaluable for this measure.</population>
          <units>nanogram*hour per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483.3" spread="13"/>
                    <measurement group_id="O2" value="1385" spread="34"/>
                    <measurement group_id="O3" value="4570" spread="23"/>
                    <measurement group_id="O4" value="10770" spread="35"/>
                    <measurement group_id="O5" value="11590" spread="28"/>
                    <measurement group_id="O6" value="22130" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PF-04937319 10 mg</title>
          <description>Participants received single oral dose of PF-04937319 10 milligram (mg) capsule on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>PF-04937319 30 mg</title>
          <description>Participants received single oral dose of PF-04937319 30 mg (3 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>PF-04937319 100 mg</title>
          <description>Participants received single oral dose of PF-04937319 100 mg (1 capsule of 80 mg and 2 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>PF-04937319 300 mg</title>
          <description>Participants received single oral dose of PF-04937319 300 mg (3 capsules of 80 mg and 6 capsules of 10 mg) on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>PF-04937319 480 mg</title>
          <description>Participants received single oral dose of PF-04937319 480 mg (6 capsules of 80 mg) on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>PF-04937319 640 mg</title>
          <description>Participants received single oral dose of PF-04937319 640 mg (8 capsules of 80 mg) on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Participants received single oral dose of placebo matched to PF-04937319 capsule on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

